Literature DB >> 21442288

Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.

Andrea Tannapfel1, Helmut Denk, Hans-Peter Dienes, Cord Langner, Peter Schirmacher, Michael Trauner, Berenike Flott-Rahmel.   

Abstract

The diagnostic procedures in patients with suspected fatty liver disease-with or without known alcohol consumption-should be standardized and generally accepted. We therefore present a guideline, summarizing the current concepts of etiology, diagnostic as well as differential diagnostic of patients with fatty liver disease. Alcoholic as well as and non-alcoholic fatty liver are characterised by lipid deposition in hepatocytes. The diagnosis of steatosis is made when lipid deposition exceeds 5% of hepatocytes, while involvement of more than 50% is called "fatty liver". An additional inflammatory reaction leads to alcoholic (ASH) or non-alcoholic steatohepatitis (NASH). Steatohepatitis is present when both inflammatory infiltrates of mixed cells in the small liver lobules as well as liver cell injury in terms of ballooning can be detected. Liver biopsy represents the "golden standard" for confirming diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease. The differential diagnosis of ASH vs. NASH cannot be made on the basis of histological criteria alone. Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a "Brunt Score" or "NAS" (NAFLD activity score), providing the basis on which to decide whether or not steatohepatitis is present. People at increased risk of developing a fatty liver possess an increased risk of developing chemotherapy-associated steatohepatitis. Histologically, pediatric NASH differs from adult NASH and is often only clinically manifest through a mild if persistent elevation in transaminases.

Entities:  

Mesh:

Year:  2011        PMID: 21442288     DOI: 10.1007/s00428-011-1066-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  81 in total

1.  Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.

Authors:  A Sonsuz; M Basaranoglu; G Ozbay
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

2.  Chemotherapy-induced steatohepatitis in colorectal cancer patients.

Authors:  Umberto Vespasiani Gentilucci; Daniele Santini; Bruno Vincenzi; Enrica Fiori; Antonio Picardi; Giuseppe Tonini
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

Review 3.  Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.

Authors:  Elizabeth M Brunt
Journal:  Semin Diagn Pathol       Date:  2005-11       Impact factor: 3.464

Review 4.  Pathological features of NASH.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  Front Biosci       Date:  2005-05-01

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 6.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Authors:  Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Journal:  Eur J Cancer       Date:  2007-09-04       Impact factor: 9.162

7.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  44 in total

1.  Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease.

Authors:  Benedikt Schaefer; David Haschka; Armin Finkenstedt; Britt-Sabina Petersen; Igor Theurl; Benjamin Henninger; Andreas R Janecke; Chia-Yu Wang; Herbert Y Lin; Lothar Veits; Wolfgang Vogel; Günter Weiss; Andre Franke; Heinz Zoller
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

2.  Schisandra chinensis prevents alcohol-induced fatty liver disease in rats.

Authors:  Hyoung Joon Park; Soo-Jung Lee; Yuno Song; Sun-Hee Jang; Yeoung-Gyu Ko; Suk Nam Kang; Byung Yeoup Chung; Hong-Duck Kim; Gon-Sup Kim; Jae-Hyeon Cho
Journal:  J Med Food       Date:  2014-01       Impact factor: 2.786

Review 3.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 4.  Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Stephanie Klein; Jean-François Dufour
Journal:  Hepat Oncol       Date:  2017-10-30

Review 5.  Pharmacotherapy of acute alcoholic hepatitis in clinical practice.

Authors:  Ludovico Abenavoli; Natasa Milic; Samir Rouabhia; Giovanni Addolorato
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 6.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

7.  Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis.

Authors:  Christoph Dorn; Jörg Heilmann; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

8.  Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice.

Authors:  Tania E Schwingel; Caroline P Klein; Natalia F Nicoletti; Cristiana L Dora; Gabriela Hadrich; Cláudia G Bica; Tiago G Lopes; Vinicius Duval da Silva; Fernanda B Morrone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-08       Impact factor: 3.000

Review 9.  The indications for liver biopsy.

Authors:  Andrea Tannapfel; Hans-Peter Dienes; Ansgar W Lohse
Journal:  Dtsch Arztebl Int       Date:  2012-07-09       Impact factor: 5.594

Review 10.  Alcoholic and non-alcoholic steatohepatitis.

Authors:  Manuela G Neuman; Samuel W French; Barbara A French; Helmut K Seitz; Lawrence B Cohen; Sebastian Mueller; Natalia A Osna; Kusum K Kharbanda; Devanshi Seth; Abraham Bautista; Kyle J Thompson; Iain H McKillop; Irina A Kirpich; Craig J McClain; Ramon Bataller; Radu M Nanau; Mihai Voiculescu; Mihai Opris; Hong Shen; Brittany Tillman; Jun Li; Hui Liu; Paul G Thomes; Murali Ganesan; Steve Malnick
Journal:  Exp Mol Pathol       Date:  2014-09-11       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.